PRINCETON, N.J.--(BUSINESS WIRE)--Cytogen Corporation (NASDAQ: CYTO) reported updated data from a Phase 1 dose escalation study evaluating QUADRAMET® (samarium Sm-153 lexidronam injection) in combination with bortezomib (Velcade®, Millennium Pharmaceuticals, Inc.) in patients with relapsed multiple myeloma. Data from 33 patients were presented today in a poster titled, “Phase 1 Trial of Bortezomib (Vel) and Samarium (Sam) in Multiple Myeloma,” by James Berenson, M.D., Medical & Scientific Director of the Institute for Myeloma & Bone Cancer Research in West Hollywood, California, at the XIth International Myeloma Workshop taking place in Greece.
